Literature DB >> 9846735

Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes.

Monique Mallea1, Jacqueline Chevalier1, Charleric Bornet1, Annie Eyraud1, Anne Davin-Regli1, Claude Bollet, Jean-Marie Pages1.   

Abstract

Enterobacter aerogenes is among the five most frequently isolated nosocomial pathogens in France, and this bacterium also shows increasing multidrug resistance. In this study, various E. aerogenes strains isolated from hospital units were characterized for their outer-membrane proteins, antibiotic susceptibilities (inhibition diameters and MICs) and resistance mechanisms associated with modification of envelope permeability (porin alteration and active efflux). Diminished outer-membrane permeability due to porin alterations was found in conjunction with the expression of an enzymic barrier in resistant isolates. Interestingly, changes in the functional expression of porins appeared to play a special role in susceptibility to cefepime. An active efflux to quinolones was also identified. Simultaneous changes in envelope permeability, i.e. a porin deficiency (in) and an efflux mechanism (out), were clearly evident in two clinical strains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846735     DOI: 10.1099/00221287-144-11-3003

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  68 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Modification of outer membrane protein profile and evidence suggesting an active drug pump in Enterobacter aerogenes clinical strains.

Authors:  Stéphane Gayet; Renaud Chollet; Gérard Molle; Jean-Marie Pagès; Jacqueline Chevalier
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.

Authors:  D Aubert; L Poirel; J Chevalier; S Leotard; J M Pages; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

5.  Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Nathalie Burggraeve; Michel Cormier; Martine Bonnaure-Mallet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

6.  The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes.

Authors:  Elizabeth Pradel; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Omp35, a new Enterobacter aerogenes porin involved in selective susceptibility to cephalosporins.

Authors:  Charléric Bornet; Nathalie Saint; Lilia Fetnaci; Myrielle Dupont; Anne Davin-Régli; Claude Bollet; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

8.  Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.

Authors:  Victor Kuete; Bathélémy Ngameni; Jean G Tangmouo; Jean-Michel Bolla; Sandrine Alibert-Franco; Bonaventure T Ngadjui; Jean-Marie Pagès
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

9.  Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel.

Authors:  V Simonet; M Malléa; J M Pagès
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

10.  Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.

Authors:  Fred C Tenover; Patti M Raney; Portia P Williams; J Kamile Rasheed; James W Biddle; Antonio Oliver; Scott K Fridkin; Laura Jevitt; John E McGowan
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.